A Pilot Study Using Magnetic Resonance (MR) to Assess Cervix Motion During Radiotherapy Treatment. (MR Cervix)
The standard treatment for locally advanced cervical cancer is concurrent chemo-radiotherapy. This treatment is associated with long term side effects in around half of patients with up to 10% suffering from grade 3-4 toxicity.
The development of intensity modulated radiotherapy (IMRT) allows for shaping of radiotherapy fields to reduce the doses delivered to organs at risk (OARs). This does appear to reduce the risk of long and short term toxicity (although there is little randomized evidence). However pelvic organ position varies both between and even during radiotherapy fractions; this means that radiotherapy margins must be generous to allow adequate coverage of the clinical target volume (CTV) but this also increases dose to OARs.
There have been a number of studies evaluating pelvic organ motion in cervical cancer as well as assessing different adaptive radiotherapy strategies. These have included individualized margins, plan of the day and adaptive techniques. Most of these studies have been carried out using cone beam computed tomography (CBCT) imaging which is often poor quality with limited soft tissue contrast. MR offers better visualization of the tumour and OARs and is used for imaged guided brachytherapy treatment.
This study will explore the role of MR imaging in adaptive radiotherapy for cervical cancer with development of a number of theoretical treatment strategies.
Visão geral do estudo
Descrição detalhada
Patients will undergo standard treatment during the study with five weeks of external beam radiotherapy (25 fractions) followed by a MR guided brachytherapy boost or external beam boost (further 10 fractions.) They will be treated with weekly cisplatin 40mg/m2 if clinically appropriate.
As part of standard treatment patients have a staging MR scan at diagnosis, a radiotherapy planning CT and an MR scan in the 4th week of treatment. Cone beam imaging will also be performed. Response will be assessed as standard with a MR scan at 3 months.
As part of the study patients will undergo 3 additional MR scans. These will take place in the 1st, 2nd and 5th weeks of treatment. Extra sequences will be added to the clinical mid-point scan in the 4th week of treatment. These MR scans will include anatomical images - with full and empty bladder as well as cine data (with a scan every minute for 10 minutes) to assess intra fraction motion. They will also include a DWI sequence, which will be used to assess if early prediction of response is possible. The frequency of cone beam imaging will be increased from approximately 10 scans as standard of care to 25 scans to allow for daily imaging.
The 1st MR scan will be contoured to outline clinical target volumes (CTVs) and OARs. A variety of planning strategies will be developed including standard planning target volume (PTV) margins, a plan of the day (POTD) approach, a POTD+ as well as an online adaptation model. These models will be used to assess coverage of CTV and PTV as well as dose to OARs using the scans obtained during the radiotherapy treatment. The practicality of each approach will also be assessed. Inter and intra fraction organ motion will also be analysed in order to develop patient specific models.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Greater Manchester
-
Manchester, Greater Manchester, Reino Unido, M20 4BX
- The Christie NHS Foundation Trust
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologically confirmed diagnosis of cervical cancer
- Treatment with primary curative intent
- Undergoing external beam radiotherapy (+/-chemotherapy) followed by brachytherapy or an external beam boost
- Age over 18
Exclusion Criteria:
- Any contraindications to MR identified after MR safety screening including completion of an MR Safety Screening Form (see appendix 1)
- Previous hysterectomy
- Unable to tolerate MR scans
- Metastatic disease
- Pregnancy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: MR scans
As part of the study patients will undergo 3 additional MR scans during radiotherapy treatment.
These will take place in the 1st, 2nd and 5th weeks of treatment.
|
Additional imaging using MR scans.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Coverage of the Clinical Target Volume and dose to the Organs At Risk for different adaptive radiotherapy strategies.
Prazo: 18 months
|
Coverage of the Clinical Target Volume and dose to the Organs At Risk for different adaptive radiotherapy strategies.
|
18 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Diffusion Weighted Imaging on MR prior to and during treatment and clinical response to treatment on post treatment MR scan.
Prazo: 18 months
|
Diffusion Weighted Imaging on MR prior to and during treatment and clinical response to treatment on post treatment MR scan.
|
18 months
|
|
Bladder filling using MR sequences and stratification of patients into large or small cervix motion.
Prazo: 18 months
|
Bladder filling using MR sequences and stratification of patients into large or small cervix motion.
|
18 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Marcel van Herk, University of Manchester
- Investigador principal: Ananya Choudhury, The Christie NHS Foundation Trust
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 17_RADIO_122
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer cervical
-
Virginia Commonwealth UniversityConcluídoCâncer cervical | Doença cardiovascular | Câncer de mama | Câncer de próstata | Cancer de coloEstados Unidos
-
City of Hope Medical CenterNational Cancer Institute (NCI)ConcluídoCâncer cervical | Sobrevivente de cancer | Efeitos psicossociais do câncer e seu tratamentoEstados Unidos
-
University of WashingtonNational Cancer Institute (NCI)ConcluídoMelanoma | Linfoma | Câncer cervical | Leucemia | Câncer de mama | Câncer retal | Cancer de colo | Neoplasia malignaEstados Unidos
-
Sohag UniversityInscrevendo-se por convite
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Istanbul Aydın UniversityConcluído
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
Ensaios clínicos em MR scans
-
Second Affiliated Hospital of Nanchang UniversityRecrutamentoMiopia progredindoChina
-
University Hospital TuebingenRecrutamentoCâncer de mama | Câncer de Cabeça e Pescoço | Câncer de esôfago | Câncer retal | Câncer de próstata | Câncer de fígado | OligometástaseAlemanha
-
Galapagos NVConcluído
-
Universitätsklinikum KölnGerman Federal Ministry of Education and ResearchRecrutamentoSíndrome da Articulação FacetáriaAlemanha
-
Bezmialem Vakif UniversityMuğla Sıtkı Koçman University; The Scientific and Technological Research Council... e outros colaboradoresAtivo, não recrutandoDistúrbios alimentares | Comportamento Alimentar | Complicação de Aparelho Ortodôntico | Hábito alimentarPeru
-
Philips HealthcareConcluídoMiomas uterinosChina
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...Merck KGaA, Darmstadt, GermanyConcluído
-
Philips HealthcareRescindidoMiomas uterinosEstados Unidos, Republica da Coréia, Canadá
-
Jules Bordet InstituteRecrutamento
-
MedRhythms, Inc.Alexion Pharmaceuticals, Inc.Inscrevendo-se por conviteTranstorno do Espectro Óptico da NeuromieliteEstados Unidos